Want to see UPC full AI Analyst Report?
UPC Stock Chart & Stats
$3.39
-$0.40(-10.55%)
At close: 4:00 PM EDT
$3.39
-$0.40(-10.55%)
Day’s Range― - ―
52-Week Range$2.00 - $17.96
Previous CloseN/A
Volume43.59K
Average Volume (3M)955.25K
Market Cap
$26.93M
Enterprise Value-$17.95
Total Cash (Recent Filing)$29.05M
Total Debt (Recent Filing)$9.55M
Price to Earnings (P/E)―
Beta2.48
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,008,313
10 Day Avg. Volume2,486,504
30 Day Avg. Volume955,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00082
P/FCF Ratio>-0.01
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Leverage And Stable Asset BaseManageable leverage and a relatively stable asset base provide financial flexibility during restructuring or investment. This lowers near-term solvency risk, although persistent losses could gradually weaken the equity cushion.
Improving Gross Margin And Operating PerformanceThe margin recovery and smaller operating loss suggest that cost control, pricing, or product mix may be improving. Sustaining these gains could help narrow losses, though the company remains unprofitable and requires further operating improvement.
Expanded Intellectual Property And Product PipelineAdding patent rights broadens the company’s intellectual-property base and creates potential pipeline options in therapeutic areas aligned with elderly healthcare. If development and commercialization succeed, the assets could strengthen differentiation and future revenue opportunities.
Bears Say
Multi-year Revenue Contraction And Sustained LossesThe prolonged revenue decline indicates weakened demand, distribution, or competitive positioning rather than a temporary earnings setback. Four consecutive loss-making years show that the current business model has not yet restored sufficient scale or operating leverage.
Persistent Negative Cash GenerationOngoing cash consumption means operations are not self-funding and may require external capital or balance-sheet resources. Even with improved burn versus 2024, continued negative free cash flow limits investment capacity and increases financing dependence.
Shareholder Dilution And Financing PressureThe sizable all-share acquisition increases the share count and dilutes existing holders, while new borrowing and declining equity add financing pressure. These structural changes may constrain per-share value and reduce flexibility if losses and cash burn persist.
Universe Pharmaceuticals News
UPC FAQ
What was Universe Pharmaceuticals’s price range in the past 12 months?
Universe Pharmaceuticals lowest stock price was $2.00 and its highest was $17.96 in the past 12 months.
What is Universe Pharmaceuticals’s market cap?
Universe Pharmaceuticals’s market cap is $26.93M.
When is Universe Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Universe Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Universe Pharmaceuticals overvalued?
According to Wall Street analysts Universe Pharmaceuticals’s price is currently Overvalued.
Does Universe Pharmaceuticals pay dividends?
Universe Pharmaceuticals does not currently pay dividends.
What is Universe Pharmaceuticals’s EPS estimate?
Universe Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Universe Pharmaceuticals have?
Universe Pharmaceuticals has 5,008,313 shares outstanding.
What happened to Universe Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Universe Pharmaceuticals?
Currently, no hedge funds are holding shares in UPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Universe Pharmaceuticals
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.
Technical Analysis
China Pharma Holdings
―
RedHill Biopharma
―
China SXT Pharmaceuticals
―
PainReform
―
Shuttle Pharmaceuticals Holdings, Inc.
―